RANI Rani Therapeutics Holdings, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1856725 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY448.7%
TTM net income YoY-14.6%
TTM EPS YoY90.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-530.5%
Net margin-493.0%
FCF margin-352.7%
EBITDA margin-520.6%
Returns
ROE-248.6%
ROA-103.6%
ROIC (approx.)-173.1%
Asset turnover0.21x
Leverage & solvency
Liabilities / assets21.3%
Debt / equity0.00x
Current ratio5.26x
Interest coverage-71.86x
Cash quality & payout
Operating cash flow / net income0.71x
Accruals ratio-30.2%
Payout ratio—
Capex / revenue3.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $1.63M | $1.03M | $0 | $0 | $2.72M |
| R&D expense | $20.20M | $26.68M | $39.62M | $36.61M | $26.48M |
| SG&A expense | $19.74M | $23.95M | $26.48M | $26.84M | $27.83M |
| Operating income | -$38.31M | -$53.31M | -$66.10M | -$63.45M | -$51.60M |
| Interest expense | $2.89M | $5.03M | $5.08M | $1.07M | $466,000 |
| Pretax income | — | — | -$67.88M | -$63.27M | -$53.05M |
| Income tax | $0 | $0 | $0 | $70,000 | $41,000 |
| Net income | -$29.67M | -$30.02M | -$33.97M | -$30.59M | -$8.33M |
| EBITDA | -$37.41M | -$52.29M | -$65.28M | -$62.90M | -$51.10M |
| EPS (basic) | -0.45 | -1.05 | -1.33 | -1.28 | -0.43 |
| EPS (diluted) | -0.45 | -1.05 | -1.33 | -1.28 | -0.43 |
| Weighted avg. shares (diluted) | 66,138 | 28,476 | 25,505 | 23,817 | 19,534 |
| Balance sheet | |||||
| Cash & equivalents | $18.62M | $4.26M | $6.36M | $27.51M | $117.45M |
| Short-term investments | — | — | — | $98.50M | — |
| Receivables | $2.04M | $0 | — | — | — |
| Current assets | $53.32M | $29.74M | $50.85M | $100.92M | $119.59M |
| PP&E, net | $736,000 | $1.55M | $6.11M | $6.04M | $4.61M |
| Total assets | $58.62M | $36.63M | $57.92M | $108.03M | $124.21M |
| Current liabilities | $12.67M | $19.89M | $7.99M | $4.82M | $2.64M |
| Short-term debt | $0 | $15.00M | $4.90M | $0 | — |
| Long-term debt | $0 | $9.61M | $24.48M | $29.15M | $0 |
| Total debt | $0 | $24.61M | $29.38M | $29.15M | $0 |
| Total liabilities | $17.11M | $33.14M | $32.47M | $34.02M | $2.64M |
| Shareholders' equity | $33.01M | $1.99M | $12.87M | $36.85M | $47.41M |
| Net debt | -$18.62M | $20.35M | $23.02M | $1.64M | -$117.45M |
| Cash flow statement | |||||
| Operating cash flow | -$18.71M | -$35.50M | -$51.24M | -$46.52M | -$32.24M |
| Capital expenditure | $88,000 | $268,000 | $1.23M | $1.62M | $506,000 |
| Free cash flow | -$18.80M | -$35.76M | -$52.47M | -$48.13M | -$32.75M |
| Investing cash flow | -$7.03M | $19.81M | $29.86M | -$72.44M | -$506,000 |
| Financing cash flow | $40.30M | $13.59M | $233,000 | $29.00M | $77.15M |
| Depreciation & amortization | $900,000 | $1.03M | $822,000 | $548,000 | $497,000 |
| Stock-based compensation | $11.80M | $16.03M | $19.01M | $15.78M | $22.59M |
Free plan shows the latest 5 periods; Pro shows all 6 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.